Process Research & Development at Merck & Co., Inc. operates at the interface of discovery and process chemistry as well as providing support across a variety of therapeutic modalities. This presentation will focus on my work across multiple projects, cross functional teams, therapeutic modalities, and phases of development. I will begin by highlighting the role of our Discovery Process Chemistry group in the department, describing the development of a diastereoselective Heck functionalization which enabled the discovery team to rapidly interrogate structure-activity-relationship vectors. I will then share an early development story describing an insulin-related active pharmaceutical ingredient (API) and how our biocatalysis group developed tools for protein modification. From there I will transition to our work developing commercial processes and highlight the our efforts on a Stimulator of Interferon Genes (STING) agonist. During the course of this endeavor, methodologies were discovered for the construction of 2`-fluoronucleosides. Finally, I close with a recent story related to the process development and characterization of an electrophilic fluorination/Ru-catalyzed transfer hydrogenation sequence in our synthesis of belzutifan.

Process research and development at Merck: Collaborative and cohesive work across multiple phases and modalities

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.